global biosimilars market

1. Global Biosimilars Market
Industry, Size, Share, Growth, Trends and Forecast,
2019–2029
January 2021
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved

2. Report Snippet
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved
Chapter 1 : Table of Contents
Chapter 3: Market Dynamics
Chapter 4: Global Biosimilars Market, By
Product Class
Chapter 2: Market Purview
Chapter 5: Global Biosimilars Market, By
Application
Chapter 7: Competitive Analysis Chapter 8: Company Profiles
Chapter 6: Global Biosimilars Market, By
Region
Chapter 9: Future of Market Chapter 10: About Us

3. Global Biosimilars Market
By Product Class By Region
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East & Africa
 Monoclonal Antibodies
 Recombinant Hormones
 Immunomodulators
 Anti-inflammatory Agents
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved
By Application
 Blood Disorders
 Growth Hormonal Deficiency
 Chronic and Autoimmune Disorders
 Oncology
 Other Applications
Market Segmentation

4. Table 2.1: Global Biosimilars Market Overview
Parameters 2019 (E) 2029 (F)
Global Biosimilars Market Value (US$ Bn) 9.0 Bn xxBn
By Product Class Segment with Largest Value (US$
Mn)
Monoclonal Antibodies: XXX.X Monoclonal Antibodies: XXX.X
By Product Class Segment with Highest CAGR (%)-
2019-2029
CAGR- XX.X
By Application Segment with Largest Value (US$ Mn) Oncology : XXX.X Oncology : XXX.X
By Application Segment with Highest CAGR (%)-2019-
2029
CAGR- XX.X
By Region Segment with Largest Value (US$ Mn) North America : XXX.X North America : XXX.X
By Region Segment with Highest CAGR (%)-2019-
2029
Asia Pacific: CAGR- XX.X
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved
Executive Summary (1/5)

5. Table 2.2: Global Biosimilars Market Overview
Key Market Players:
Pfizer Inc.
Eli Lilly and Company
Mylan NV
Novartis AG
Teva Pharmaceutical
Intas
Samsung Biologics Co. Ltd
Amgen
Celltrion Inc.
STADA Arzneimittel Aktiengesellschaft
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved
Executive Summary (2/5)

6. Description Figure 2.1: Global Biosimilars Market Value Share (%), By Product
Class – 2019 (E)
 The global biosimilars market was valued at USD 7,091.40
million in 2018, and is expected to reach a value of USD
30,109.95 million by 2024.
 The market is also expected to register a CAGR of 27.29%,
during the forecast period.
 Several factors may be associated with the growth of the
biosimilars market, such as several blockbuster
biopharmaceuticals that are going off-patent over the next
five to ten years, high growth potential, and increasing
demand for biosimilar drugs due to their cost effectiveness.
Monoclonal
Antibodies
Recombinant
Hormones
Immunomodulators
Anti-inflammatory
Agents
Figure 2.2: Global Biosimilars Market Value Share (%), By
Application – 2019 (E)
Blood Disorders
Growth Hormonal
Deficiency
Chronic and
Autoimmune Disorders
Oncology
Other Application
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved
Executive Summary (3/5)

7. North America
Europe
Latin America
Asia Pacific
Middle East & Africa
XX.X%
Figure 2.3: Global Biosimilars Market Value Share (%), By Region –
2019 (E)
 On region the global immune health supplements market is
segmented into North America, Europe, Asia Pacific, Latin
America, and Middle East & Africa. The European region is
dominating the immune health supplements market
followed by the Asia Pacific.
 The United States entered this market only in 2015, when
the first drug, Zarxio, manufactured by Sandoz, was
approved by the FDA. In April 2017, the FDA approved the
fifth biosimilar, RENFLEXIS (infliximab - abda), under a
global biosimilars development and commercialization
agreement between Merck and Samsung
 Bioepis Co. Ltd. Due to this aggressive strategy from both
manufacturers and regulatory authorities, the size of the US
biosimilar segment skyrocketed over the last two years.
This trend of growth is expected to continue over the
forecast period, as a huge number of blockbuster drugs,
which garner sales of billions of US dollars, are about to
lose their patents during the next two to three years.
 The recent patent expiration of major biologics has
significantly helped the biosimilars business across the
United Kingdom. The past three years have observed
consistent growth in the sales of renowned biosimilars,
such as Infliximab, Etanercept, and Rituximab.
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved
Analysis and Outcome
Executive Summary (4/5)

8. 27.29%
Market at Glance
2019
2029
CAGR 019-2029
xxBn
9.0Bn
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved
Executive Summary (5/5)

9. Market Dynamics
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved
Chapter 3

10. About Us
Disclaimer
 The material is based on sources which we believe are reliable, but no warranty, either expressed or implied, is provided in relation to
the accuracy or completeness of the information. The views expressed are our best judgment as of the date of issue and are subject to
change without notice. Prophecy Market Insights takes no responsibility for decisions made on the basis of these opinions.
 Any redistribution of this information is strictly prohibited. Copyright © 2019 Prophecy Market Insights pvt. Ltd , all rights reserved.
Legal and Copyright Notices
 While the editors endeavor to ensure the accuracy of all information and data contained in this Market Research Report, neither they
nor Prophecy Market Insights Pvt. Ltd. accept responsibility for any loss or damage (whether direct or indirect) whatsoever to the
customer or any third party resulting or arising there from.
 All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or
mechanical, including photocopying, recording, taping, or information storage and retrieval systems without permission of the publisher.
Disclaimer:
Prophecy market Insights Pvt. Ltd attempts to ensure that the information provided in our market research reports is as accurate and
complete as possible, the quantity of detailed information used and the fact that some of the information (which cannot always be verified
or validated) is supplied by third parties and sources not controlled by prophecy market Insights Pvt. ltd means that we cannot always
guarantee the accuracy, completeness or originality of the information in some reports, and we are therefore not responsible for any errors
or omissions in those reports. The recipients of these reports are responsible for determining whether the information contained therein is
sufficient for use and shall use their own skill and judgement when choosing to rely upon the reports
Copyright © PROPHECY MARKET INSIGHTS 2021, All Rights Reserved

11. To know more about us, please visit our website:
www.prophecymarketinsights.com
For sales queries or new topics email us on:
sales@prophecymarketinsights.com
For other queries contact:
Shweta R
Email: shweta.r@prophecymarketinsights.com
(Global Head - Business Development)
Prophecy Market Insights
Email: sales@prophecymarketinsights.com